In this study the contribution of activation ofthe contact system to activation of the fibrinolytic system in vivo was investigated in healthy volunteers and in factor XII deficient patients.
Introduction
The conversion of the fibrinolytic proenzyme plasminogen into the proteolytic enzyme plasmin may occur in vivo via This study was presented in part at the combined 23rd Congress ofthe International Society ofHematology and the 32nd Annual Meeting of the American Society of Hematology, 28 November-4 December 1. Abbreviations used in this paper: ANOVA, analysis of variance; DDAVP, desamino -arginine vasopressin; PAP, plasmin-a2-antiplasmin; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator.
several pathways (1, 2) . The two most extensively studied are the tissue-type plasminogen activator (t-PA)1 and urokinasetype plasminogen activator (u-PA) dependent pathways. The exact contribution of both pathways to the development of endogenous fibrinolytic activation under basal and activated conditions has not been precisely determined.
Activation ofplasminogen in vivo can reproducibly be studied by a short lasting infusion ofdesamino D-arginine vasopressin (DDAVP). This substance induces increases in plasma levels of plasminogen activator activity and of both t-PA and u-PA antigen (3) (4) (5) . In addition, it induces activation of plasminogen in vivo as reflected by increasing levels of plasmin-a2-antiplasmin (PAP) complex levels (Levi, M., et al., manuscript submitted for publication). Previous experiments have shown that quenching of both t-PA and u-PA by specific antibodies in plasma obtained from healthy volunteers shortly after infusion of DDAVP, does not completely abolish plasminogen activator activity (5) , indicating the existence of a third pathway of plasminogen activation. This third pathway of plasminogen activation has been claimed to be dependent on activation of the contact system of blood coagulation (6) . Involvement of the contact system (for reviews see Colman et al. [71 and Kaplan et al. [8] ) in fibrinolysis is supported by several lines of evidence. First, patients with severe factor XII deficiency have a higher incidence of thromboembolic events, which might be attributed to an impaired fibrinolytic activity (9, 10) . Second, recent observations in patients with hereditary angioedema, which is caused by a deficiency ofthe major inhibitor of the contact system, Cl-inhibitor, have shown that increased activity of the contact system is associated with an enhanced plasmin generation (11) . Finally, factor XII structurally resembles t-PA and plasminogen (12) .
To determine the role of contact activation in fibrinolysis we investigated the effect of intravenous administration of DDAVP on the activation ofthe contact system and the fibrinolytic system in healthy subjects and individuals with mild or severe factor XII deficiency. In addition, we studied the contribution of factor XII to the plasminogen activator activity induced in plasma by DDAVP in these subjects. Our results show that DDAVP in vivo induces activation of the contact system and the generation of plasminogen activator activity and plasmin generation which is dependent in part on factor XII. This response was impaired in factor XII deficient patients.
Methods
Study subjects and DDA VP test. Six healthy volunteers (aged 21-33 yr) and in addition six subjects with a known deficiency of coagulation factor XII were studied. Of the deficient subjects, three patients (aged 21-28 yr) had factor XII activity levels below 1% (severe factor XII deficiency) while three other patients (aged yr) had factor XII activity levels ranging from 20% to 35% (mild factor XII deficiency).
They were seated 10 min before and during the entire experiment, fasted overnight, and abstained from smoking for 12 h before the experiment. The DDAVP infusion started at 9:00 a.m. The study was approved by the Institutional Review Board.
Collection ofblood. Blood was collected by separate venipunctures before and at 15, 30, and 60 min after the start ofthe DDAVP infusion. If post-DDAVP plasma is mentioned further, the sample taken 15 min after the start of the infusion is referred to.
Blood (9 vol) for the measurement of plasminogen activator activity, t-PA antigen, u-PA antigen, factor XII activity, factor XII antigen, and prekallikrein antigen was collected in plastic syringes containing 3.2% sodium citrate (1 vol) . For the measurement of PAP complexes, factor XII-Cl-inhibitor complexes and kallikrein-Cl-inhibitor complexes blood was collected in siliconized vacutainer tubes (Becton Dickinson, Plymouth, UK) to which Polybrene (hexadimethrine bromide; Janssen Pharmaceutica, Beerse, Belgium) and EDTA (0.05% wt/ vol and 10 mM, respectively, final concentrations) were added to prevent in vitro complex formation. All blood samples were immediately immersed in melting ice and centrifuged at 4VC for 20 min at 1,600 g. Plasma samples were stored at -70'C until assayed.
Measurement offibrinolytic activation. Plasminogen activatoractivity was assayed by an amidolytic assay (13) . Briefly, 25 y1 of euglobulin fraction of plasma was mixed to a final vol of 250 ,g with 0.1 mol/liter Tris HCI pH 7.5, 0.1% (vol/vol) Tween 80, 0.30 mmol/liter S-2251 (Kabi Haematology, Molndal, Sweden), 0.13 mol/liter plasminogen, and 0.12 mg/ml CNBr fragments of fibrinogen (both obtained from Kabi Haematology). The assay was performed in the absence and presence of specific antibodies against t-PA (0.25 ,ug/ml), u-PA (0.25 tg/ ml), or factor XII (0.25 ug/ml), and mixtures of these antibodies. The antibodies used in this assay were affinity purified monospecific polyclonal rabbit antibodies against t-PA or u-PA, obtained as described previously (14) , or monoclonal antibody OT-2, which was raised against factor XII and inhibits amidolytic activity of factor XIIa (Dors, D., manuscript in preparation). Antibodies were added in excess, as was revealed by similar inhibition results upon incubation with a fivefold higher or lower antibody concentration (data not shown). Results were expressed in percentage of plasminogen activator activity in the post-DDAVP plasma samples in the absence of antibodies.
t-PA antigen was measured with an ELISA (Diagnostica Stago, Asnieres-sur-Seine, France) (15) . u-PA antigen was measured with a sandwich ELISA, as described before (16) . Plasmin-a2-antiplasmin complex levels were determined by an RIA as previously described ( XII or prekallikrein in this plasma. These antigen assays measure factor XII or prekallikrein irrespective of its molecular forms, i.e., native protein or activated protein in complex with Cl-inhibitor. Factor XIIa-CI-inhibitor complexes and kallikrein-CI-inhibitor complexes were assayed by RIA as described previously (17) . Briefly, a monoclonal antibody that specifically binds complexed Cl-inhibitor (KOK-12) was coupled to Sepharose and incubated with plasma samples. Bound factor XII-or kallikrein-Cl-inhibitor complexes were quantitated by subsequent incubation with either '251-labeled polyclonal anti-factor XII or '25M-labeled anti-kallikrein antibodies, respec-
tively. Results obtained with tested plasma samples were expressed in milliunits, as calculated by reference to a standard curve that consisted of dextran sulphate-activated pooled plasma (which contains 1 U of complexes per ml).
Statistical analysis. Means of multiple groups were compared with analysis ofvariance using the Newman-Keuls' test to correct for multiple comparison. Student's t test was used to compare means between paired groups. All calculations were done using the Number Cruncher Statistical Package (Number Cruncher Statistical System, Kaysville, UT). P values below 0.05 were considered statistically significant.
Results
Plasminogen activator activity induced by DDA VP in normal subjects. Plasma levels ofplasminogen activating activity, t-PA antigen and u-PA antigen before and 15 min after the infusion of DDAVP in healthy volunteers are given in Table I . As expected, the infusion of DDAVP in healthy volunteers resulted in a significant nearly sevenfold increase in fibrinolytic activity as reflected by the increase in plasminogen activating activity. Plasma levels of t-PA antigen and u-PA antigen increased 3.7-fold and 1.7-fold, respectively. Fig. 1 shows the effect of the addition of anti-t-PA, anti-u-PA, anti-factor XII, or mixtures of these antibodies on plasminogen activating activity in post-DDAVP plasma ofhealthy volunteers. Addition ofanti-t-PA antibody resulted in an inhibition of plasminogen activating activity of 59% (SEM 4.4) whereas addition of anti-u-PA antibody reduced plasminogen activating activity with 24% (SEM 4.9). The combination of anti-t-PA and anti-u-PA antibodies did not completely inhibit plasminogen activating activity (mean inhibition 77%, SEM .-_,-.
'. -I .:...: total factor XII < 1 % I'All complexes healthy volunteers. There was no significant difference in the inhibition of plasminogen activating activity by either anti-t-PA or anti-u-PA antibodies between the healthy subjects and the factor XII deficient subjects. However, the residual plasminogen activating activity observed after the addition ofboth anti-t-PA and anti-u-PA antibodies was significantly reduced in plasma of patients with mild factor XII deficiency (14%, SEM 1.2, P < 0.05 Student's t test) compared to that in healthy volunteers (23%, SEM 2.1) and was completely absent in patients with severe factor XII deficiency (0%, SEM 0.3, P < 0.05). Induction ofPAP complexes by DDA VP in healthy subjects and in patients with factor XII deficiency. The increase in plasminogen activating activity resulted in the formation of plasmin as indicated by the increase in plasma levels of PAP complexes upon the infusion of DDAVP. Response of PAP complexes in plasma upon DDAVP in healthy subjects and factor XII deficient individuals is shown in Fig. 3 compared to normal subjects, Student's t test). The level of PAP complexes in plasma after DDAVP in patients with mild deficiency of factor XII was between that observed in patients with severe deficiency of factor XII and that seen in healthy subjects (Fig. 3, preinfusion Activation ofthe contact system induced by DDA VP. PAP complexes were significantly lower in the patients with severe factor XII deficiency upon administration of DDAVP compared to normal controls. In addition, DDAVP generated a factor XII dependent plasminogen activating activity in healthy subjects. These results might point to contact activation and subsequent additional plasmin generation induced by DDAVP. We therefore decided to study activation of the contact system during DDAVP infusion.
The effect of the infusion of DDAVP in healthy subjects and factor XII deficient patients on factor XII activity is shown in Fig. 4 . A small but significant increase in factor XII activity was observed in all healthy subjects peaking at 30 min after the start of the DDAVP infusion (mean preinfusion level 98%, Figure 5 . Activation of the contact system upon intravenous administration of DDAVP to normal individuals (o, n = 6) and to patients with mild (a, n = 3) and severe (A, n = 3) factor XII deficiency. tients with a mild factor XII deficiency. Factor XII activity levels in these patients increased from 31% (SEM 6.4) to 61% (SEM 4.0). Factor XII activity was not detected at any stage of the study in patients with a severe factor XII deficiency indicating that the increases observed in the other groups were indeed due to factor XII. In contrast to functional levels, factor XII antigen levels remained stable during the entire study period both in healthy subjects and in factor XII deficient patients (Table II) .
Results ofthe infusion ofDDAVP on factorXIIa-C -inhibitor complexes are shown in Fig. 5 a. An increase in plasma levels of factor XIIa-Cl-inhibitor complexes was observed in all healthy subjects and in patients with a mild factor XII deficiency. Mean preinfusion plasmalevel offactor XIa-C I -inhibitor complexes in healthy volunteers was 43 mU (SEM 5.1) and increased upon infusion of DDAVP to a mean maximal level of 87 mU (SEM 8.3, P < 0.05, ANOVA and Newman-Keuls' test) at 30 min after the start of the infusion. Patients with a mild deficiency of factor XII had lower preinfusion levels (mean 26 mU, SEM 4.7) which increased to 61 mU (SEM 7.0, P < 0.05, ANOVA and Newman-Keuls' test) at 30 min. In the patients with severe factor XII deficiency no factor XIIa-C 1-in-hibitor complexes were detected in any of the blood samples studied (i.e., levels were < 10 mU/ml). Mean kallikrein-Cl-inhibitor complex levels increased from 30 mU (SEM 4.6) to 49 mU (SEM 7.1) at 30 min in normal subjects and from 24 mU (SEM 5.3) to 42 mU (SEM 7.3) at 30 min in patients with a mild factor XII deficiency (Fig.  5 b) . Both increases were not statistically significant. Plasma levels of kallikrein-C 1-inhibitor complexes in subjects with severe factor XII deficiency were the lowest compared to the other groups and they remained stable during the DDAVP infusion. Plasma levels ofprekallikrein showed no change during the study in all groups (Table II) .
Discussion
Deficiency of factor XII results in a prolongation of coagulation tests in vitro, which may suggest the association with a bleeding tendency in affected individuals. However, in vivo these individuals rather seem to have a higher incidence of thromboembolism (9, 10) , as was illustrated by the clinical course of the index case, Mr. Hageman, who died of pulmonary embolism (18, 19) . The data presented here show that activation of the contact system contributes to plasminogen activation, induced in vivo by intravenous administration of DDAVP. Therefore, we propose that the thromboembolic events that are observed in factor XII deficient individuals are due to impaired fibrinolysis.
Activation of the contact system by DDAVP as demonstrated by an increase in factor XIIa-C 1-inhibitor complexes presumably was responsible for the observed non-t-PA and non-u-PA related plasminogen activator activity in post-DDAVP plasma for two reasons. First, this residual plasminogen activator activity could be quenched with a monoclonal antibody that specifically blocks factor XII activity. Second, this non-t-PA and non-u-PA dependent plasminogen activator activity was reduced in patients with half-normal levels of factor XII and completely absent in patients with no detectable factor XII. The relevance ofthis factor XII dependent plasminogen activator activity in vivo was demonstrated by the observation that activation ofplasminogen in vivo as reflected by the increase in PAP complexes was significantly reduced in severely factor XII deficient patients compared to healthy controls. This difference between PAP complex levels upon DDAVP was not due to a diminished t-PA or u-PA increase in the factor XII deficient patients (Table I) . Therefore, these findings imply that activation of the contact system contribute to activation of the fibrinolytic system in vivo.
Earlier observations revealed the absence of prothrombin Several studies have shown an increase in factor XII activity upon DDAVP (20, 21) with the exception of one report (22) . In our study we also observed an increase in the factor XII activity upon the administration of DDAVP to normal subjects; however, the total factor XII antigen level remained stable. In addition, we observed significant increases in plasma levels of factor XIIa-C1-inhibitor complexes, indicating factor XII activation in vivo (17, 23) . Presumably, the increase in factor XII activity noted after DDAVP was due to the fact that activated factor XII is more easily detected in the functional assay than native factor XII. Thus, DDAVP induced activation of native factor XII already present in the circulation rather than an increase in availability of factor XII. The mechanism of this activation induced by DDAVP is not fully understood. It has been shown that trace amounts of plasmin can activate factor XII (24, 25) . Therefore, plasmin formation by the t-PA and u-PA release upon infusion of DDAVP may initiate contact system activation which then itself may further enhance fibrinolytic activation.
Several mechanisms by which the contact system may induce plasminogen activation can be envisaged. Active factor XII is able to directly activate plasminogen (26) . However, at plasma concentrations the direct effect of factor XII on the activation ofplasminogen is presumed to be very small (6, 27) . Since, however, plasma kallikrein and factor XIa also are able to directly convert plasminogen into plasmin (7, 27) , a combined effect of factor XIIa, kallikrein, and factor XIa may potentially cause contact activation dependent fibrinolytic activity. Other studies, such as those in which dextran sulphate-activated euglobulins are studied, have shown that kallikrein is able to cleave and thereby activate single chain u-PA (28) . It has been proposed that via this mechanism the contact system contributes to plasminogen activator activity. However, such a mechanism cannot explain the contact system mediated fibrinolytic activation that we describe here, since the factor XII dependent fibrinolytic activity was still observed after specific inhibition of u-PA. Thus, the contact system dependent plasminogen activator activity as observed in this study apparently occurred via a factor XII dependent pathway that was independent from u-PA. The molecular basis for this pathway remains to be established, although several studies have proposed the involvement of a yet unidentified plasminogen activator that is dependent on factor XII (6, 29) .
Activation of the contact system results in the release of bradykinin from high molecular weight kininogen (7) . Bradykinin potentially may affect fibrinolytic activation by inducing plasminogen activator release from the vessel wall (30, 31). However, it is unlikely that this mechanism significantly contributed to the activation of the fibrinolytic system since patients with severe factor XII deficiency had no detectable contact system activation upon DDAVP (Fig. 5) , whereas they showed identical t-PA and u-PA release compared to healthy subjects.
In conclusion, infusion of DDAVP induces plasminogen activator activity that is related to activation of the contact system and, in particular, factor XII, and that occurs in addition to an increase in t-PA and u-PA activity. Therefore, we suggest that the contact system should be considered as a fibrinolytic rather than a blood coagulation system and that the association between thromboembolic disease and deficiencies ofthe contact system are due to an impaired fibrinolytic capacity in these patients.
